Heart Valve Disease
3
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
1 program1
Aortic valve replacementPhase 41 trial
Active Trials
NCT00187304Withdrawn0
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbottAortic valve replacement
BiomedPhytine
CSL SeqirusHuman fibrinogen concentrate
Clinical Trials (3)
Total enrollment: 276 patients across 3 trials
ACTION - Anticoagulation Treatment Influence on Post-operative Patients
Start: Sep 20050
Phase 4Withdrawn
Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications
Start: Aug 2009Est. completion: Oct 2012250 patients
Phase 2/3Unknown
RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery
Start: Jan 2011Est. completion: May 201326 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.